Genmab A/S, a biotechnology firm based in Copenhagen, Denmark, specializes in the discovery and development of innovative antibody-based treatments for various forms of cancer and other serious conditions. The company currently commercializes several key therapeutic antibodies. DARZALEX (daratumumab) is utilized in the treatment of multiple myeloma (MM), specific non-MM blood cancers, and AL amyloidosis. Other marketed offerings include teprotumumab for thyroid eye disease, ofatumumab, which addresses chronic lymphocytic leukemia (CLL) and multiple sclerosis, and Amivantamab for advanced or metastatic non-small cell lung cancer (NSCLC) as well as gastric or esophageal cancers. Genmab maintains an extensive and active development pipeline, featuring a broad range of experimental therapies. This includes GEN1047, tisotumab vedotin (targeting cervical, ovarian, and other solid cancers), and bispecific antibodies such as DuoBody-PD-L1x4-1BB and DuoBody-CD40x4-1BB, which are engineered for solid tumors. Epcoritamab is being developed for relapsed/refractory diffuse large B-cell lymphoma and CLL, while HexaBody-CD38 and DuoHexaBody-CD37 are designed to treat hematological malignancies. Further assets in the pipeline encompass Teclistamab, currently in Phase 2 clinical trials for vaso-occlusive crises, Camidanlumab tesirine for Hodgkin lymphoma and solid tumors, JNJ-64007957 and JNJ-64407564 for MM, PRV-015 for celiac disease, Mim8 for haemophilia A, and Lu AF82422 for multiple system atrophy. Additionally, the company is engaged in approximately 20 pre-clinical research programs. Strategic collaborations are a cornerstone of Genmab's operational model. It holds a commercial license and co-development agreement with Seagen Inc. for tisotumab vedotin. The company also partners with CureVac AG on the research and development of mRNA-based antibody products, with argenx for the discovery of novel therapeutic antibodies in immunology and oncology, and with AbbVie for the development of epcoritamab. Other notable collaborators include BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was established in 1999 and is headquartered in Copenhagen, Denmark.
Previous close
$50.60
−$0.75 · -1.46%
Regular session · ET · Market data may be delayed.
Genmab A/S, a biotechnology firm based in Copenhagen, Denmark, specializes in the discovery and development of innovative antibody-based treatments for various forms of cancer and other serious conditions. The company currently commercializes several key therapeutic antibodies. DARZALEX (daratumumab) is utilized in the treatment of multiple myeloma (MM), specific non-MM blood cancers, and AL amyloidosis. Other marketed offerings include teprotumumab for thyroid eye disease, ofatumumab, which addresses chronic lymphocytic leukemia (CLL) and multiple sclerosis, and Amivantamab for advanced or metastatic non-small cell lung cancer (NSCLC) as well as gastric or esophageal cancers. Genmab maintains an extensive and active development pipeline, featuring a broad range of experimental therapies. This includes GEN1047, tisotumab vedotin (targeting cervical, ovarian, and other solid cancers), and bispecific antibodies such as DuoBody-PD-L1x4-1BB and DuoBody-CD40x4-1BB, which are engineered for solid tumors. Epcoritamab is being developed for relapsed/refractory diffuse large B-cell lymphoma and CLL, while HexaBody-CD38 and DuoHexaBody-CD37 are designed to treat hematological malignancies. Further assets in the pipeline encompass Teclistamab, currently in Phase 2 clinical trials for vaso-occlusive crises, Camidanlumab tesirine for Hodgkin lymphoma and solid tumors, JNJ-64007957 and JNJ-64407564 for MM, PRV-015 for celiac disease, Mim8 for haemophilia A, and Lu AF82422 for multiple system atrophy. Additionally, the company is engaged in approximately 20 pre-clinical research programs. Strategic collaborations are a cornerstone of Genmab's operational model. It holds a commercial license and co-development agreement with Seagen Inc. for tisotumab vedotin. The company also partners with CureVac AG on the research and development of mRNA-based antibody products, with argenx for the discovery of novel therapeutic antibodies in immunology and oncology, and with AbbVie for the development of epcoritamab. Other notable collaborators include BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was established in 1999 and is headquartered in Copenhagen, Denmark.
Day range
Current $50.60
52-week range
Current $50.60
Regular session · ET · Market data may be delayed.
GoAI Score
Buy
Valuation
76
Undervalued
Sentiment
64
Bullish
Risk
34
Moderate Risk
Momentum
62
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Genmab A/S, a biotechnology firm based in Copenhagen, Denmark, specializes in the discovery and development of innovative antibody-based treatments for various forms of cancer and other serious conditions. The company currently commercializes several key therapeutic antibodies. DARZALEX (daratumumab) is utilized in the treatment of multiple myeloma (MM), specific non-MM blood cancers, and AL amyloidosis. Other marketed offerings include teprotumumab for thyroid eye disease, ofatumumab, which addresses chronic lymphocytic leukemia (CLL) and multiple sclerosis, and Amivantamab for advanced or metastatic non-small cell lung cancer (NSCLC) as well as gastric or esophageal cancers. Genmab maintains an extensive and active development pipeline, featuring a broad range of experimental therapies. This includes GEN1047, tisotumab vedotin (targeting cervical, ovarian, and other solid cancers), and bispecific antibodies such as DuoBody-PD-L1x4-1BB and DuoBody-CD40x4-1BB, which are engineered for solid tumors. Epcoritamab is being developed for relapsed/refractory diffuse large B-cell lymphoma and CLL, while HexaBody-CD38 and DuoHexaBody-CD37 are designed to treat hematological malignancies. Further assets in the pipeline encompass Teclistamab, currently in Phase 2 clinical trials for vaso-occlusive crises, Camidanlumab tesirine for Hodgkin lymphoma and solid tumors, JNJ-64007957 and JNJ-64407564 for MM, PRV-015 for celiac disease, Mim8 for haemophilia A, and Lu AF82422 for multiple system atrophy. Additionally, the company is engaged in approximately 20 pre-clinical research programs. Strategic collaborations are a cornerstone of Genmab's operational model. It holds a commercial license and co-development agreement with Seagen Inc. for tisotumab vedotin. The company also partners with CureVac AG on the research and development of mRNA-based antibody products, with argenx for the discovery of novel therapeutic antibodies in immunology and oncology, and with AbbVie for the development of epcoritamab. Other notable collaborators include BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was established in 1999 and is headquartered in Copenhagen, Denmark.
Day range
Current $50.60
52-week range
Current $50.60
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 3.72B USD | 21.53B USD | 16.47B USD | 14.51B USD | 8.42B USD |
| Cost of goods sold | 309.24M USD | 985M USD | 226M USD | — | — |
| Gross profit | 3.41B USD | 20.54B USD | 16.25B USD | 14.51B USD | 8.42B USD |
| Research and development | 1.56B USD | 9.75B USD | 7.63B USD | 5.56B USD | 4.18B USD |
| Selling, general, and administrative | 602.47M USD | 3.79B USD | 3.3B USD | 2.68B USD | 1.28B USD |
| Operating expenses | 2.16B USD | 13.84B USD | 10.93B USD | 8.24B USD | 5.46B USD |
| Interest income | 138.11M USD | 995M USD | 939M USD | 324M USD | 197M USD |
| Interest expense | 61.05M USD | 120M USD | 27M USD | 21M USD | 13M USD |
| Depreciation and amortization | 71.06M USD | 413M USD | 293.62M USD | 362M USD | 248.99M USD |
| Operating income | 1.25B USD | 6.7B USD | 5.32B USD | 6.27B USD | 2.95B USD |
| Net income | 963.76M USD | 7.84B USD | 4.35B USD | 5.45B USD | 2.96B USD |
Company facts updated Nov 22, 2026.
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Biotechnology ETFIBB216.92M2.07%10.53B USD0.44%$199.54-2.05%
First Trust NYSE Arca Biotechnology Index FundFBT134.86M4.70%2.87B USD0.55%$257-2.20%
Avantis International Equity ETFAVDE26.67M0.14%18.31B USD0.23%$82.46-2.61%
Tema Oncology ETFCANC12.61M6.49%194.19M USD0.99%$37.5165-2.07%
First Trust Nasdaq BuyWrite Income ETFFTQI3.55M0.40%894.31M USD0.75%$19.46-3.85%
Harding Loevner International Developed Markets Select Equity ETFLOEV2.9M3.53%82.8M USD0.70%$14.98-2.47%
John Hancock Investments - Multifactor Developed International ETFJHMD2.75M0.29%942.38M USD0.39%$41.50-2.56%
Fidelity Nasdaq Composite Index ETFONEQ1.37M0.01%10.45B USD0.21%$89.52-4.94%
iShares Biotechnology ETFIBB
First Trust NYSE Arca Biotechnology Index FundFBT
Avantis International Equity ETFAVDE
Tema Oncology ETFCANC
First Trust Nasdaq BuyWrite Income ETFFTQI
Harding Loevner International Developed Markets Select Equity ETFLOEV
John Hancock Investments - Multifactor Developed International ETFJHMD
Fidelity Nasdaq Composite Index ETFONEQAI-generated and delayed market data for informational and educational purposes only. Not investment advice.